Investments

Clinical Candidates

Eight GHIT development partnerships have conducted successful late-stage projects in Africa and South America. As a result, and numerous promising global health innovations are now firmly within reach.

DSM265
Malaria / Drug
Development Stage: Phase IIb
Country: To be determined
https://www.ghitfund.org/investment/portfoliodetail/detail/112
E1224
Chagas disease / Drug
Development Stage: Phase IIb
Country: Bolivia
https://www.ghitfund.org/investment/portfoliodetail/detail/26
PZQ
Schistosomiasis / Pediatric Drug
Development Stage and Country:
Phase IIb (Ivory Coast) / Phase III (Kenya)
https://www.ghitfund.org/investment/portfoliodetail/detail/103
DAR-901
Tuberculosis / Vaccine
Development Stage: Phase IIb
Country: Tanzania
https://www.ghitfund.org/investment/portfoliodetail/detail/70
BK-SE36/CpG
Malaria / Vaccine
Development Stage: Phase Ib
Country: Burkina Faso
https://www.ghitfund.org/investment/portfoliodetail/detail/99
SJ733
Malaria / Drug
Development Stage: Phase IIa
Country: To be determined
https://www.ghitfund.org/investment/portfoliodetail/detail/106
TB-LAM
Tuberculosis / Diagnostic
Development Stage: Product validation
Country: South Africa
https://www.ghitfund.org/investment/portfoliodetail/detail/126
E1224
Mycetoma / Drug
Development Stage: Phase IIb
Country: Sudan
https://www.ghitfund.org/investment/portfoliodetail/detail/114